Literature DB >> 25253423

Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement.

Mohammad-Ali Haghsheno1, Dan Mellström, Ralph Peeker, Jan Hammarsten, Mattias Lorentzon, Valter Sundh, Magnus Karlsson, Claes Ohlsson, Jan-Erik Damber.   

Abstract

OBJECTIVE: The aim of this study was to test whether lower urinary tract symptoms (LUTS) and urinary incontinence are associated with the metabolic syndrome (MetS). The association between LUTS and benign prostatic enlargement (BPE) was also investigated.
MATERIAL AND METHODS: A cross-sectional, representative risk factor analysis of LUTS, as measured by the International Prostate Symptom Score (IPSS), and urinary incontinence was conducted. Among 950 representative individuals, aged 69-81 years, the association between clinical, anthropometric, endocrine, metabolic and inflammatory factors on the one hand, as both major and minor aspects of MetS, and LUTS and urinary incontinence, on the other hand, was analysed. The prostate gland volume was measured in a subgroup of 155 randomly selected individuals and the association between LUTS and BPE was estimated.
RESULTS: No significant association was found between LUTS or urinary incontinence and the major aspects of the MetS. However, in a multivariate analysis, serum serotonin showed an independent negative correlation with LUTS and with urinary incontinence while fasting serum glucose and serum adiponectin showed a positive correlation with LUTS. Furthermore, in a subgroup of 155 individuals, the prostate gland volume correlated positively with LUTS.
CONCLUSIONS: The study did not show an association between LUTS or urinary incontinence and the major components of the MetS. However, serum serotonin showed an independent negative correlation with LUTS and with urinary incontinence while fasting serum glucose and serum adiponectin showed a positive correlation with LUTS. The data confirm the general knowledge that BPE may be one of the causative factors of LUTS.

Entities:  

Keywords:  benign prostatic enlargement; lower urinary tract symptoms; serotonin; urinary incontinence

Mesh:

Substances:

Year:  2014        PMID: 25253423     DOI: 10.3109/21681805.2014.936495

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  6 in total

Review 1.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

Review 2.  Overactive bladder in children.

Authors:  Israel Franco
Journal:  Nat Rev Urol       Date:  2016-08-17       Impact factor: 14.432

Review 3.  Androgens, aging, and prostate health.

Authors:  Karin Welén; Jan-Erik Damber
Journal:  Rev Endocr Metab Disord       Date:  2022-06-24       Impact factor: 6.514

4.  Serotonin regulates prostate growth through androgen receptor modulation.

Authors:  Emanuel Carvalho-Dias; Alice Miranda; Olga Martinho; Paulo Mota; Ângela Costa; Cristina Nogueira-Silva; Rute S Moura; Natalia Alenina; Michael Bader; Riccardo Autorino; Estêvão Lima; Jorge Correia-Pinto
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

5.  Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.

Authors:  Asma Omran; Bianca M Leca; Eduard Oštarijaš; Natasha Graham; Ana Sofia Da Silva; Zoulikha M Zaïr; Alexander D Miras; Carel W le Roux; Royce P Vincent; Linda Cardozo; Georgios K Dimitriadis
Journal:  Ther Adv Endocrinol Metab       Date:  2021-12-08       Impact factor: 3.565

6.  Effects of testosterone replacement on serotonin levels in the prostate and plasma in a murine model of hypogonadism.

Authors:  Paulo Mota; João Barbosa-Martins; Rute S Moura; Estêvão Lima; Alice Miranda; Jorge Correia-Pinto; Emanuel Carvalho-Dias
Journal:  Sci Rep       Date:  2020-09-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.